- Details
- Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression....
|
- Details
- Alicia Morgans and Arun Azad discuss a post hoc analysis of the ARCHES trial data presented at GU ASCO 2022 of overall survival by disease volume and progression to M1 HSPC after initial diagnosis with localized disease or presentation of de novo mHSPC at initial diagnosis. Biographies: Arun Azad, MBBS, PhD, FRACP, Medical Oncologist, Associate Professor, Department of Medicine, Peter MacCallum Ca...
|
- Details
- Thomas Keane is joined by Heather Payne to discuss the management of metastatic hormone-sensitive prostate cancer. While treatment with androgen deprivation therapy (ADT) provides initial responses, progression is common and a large proportion of prostate cancer-related deaths occur among men initially diagnosed with metastatic disease. Dr. Payne focuses her discussion on multiple trials determini...
|
- Details
- Neal Shore joins Alicia Morgans to discuss his presentation from the American Urologic Association (AUA) annual meeting titled "Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer Patients Who Received Prior Anti androgen Therapy: PostHoc Analysis of ARCHES." This post hoc analysis aimed to evaluate the efficacy of enzalutamide + androgen deprivation therapy (ADT) versus placebo + ADT in...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Efficacy of Enzalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: a Post Hoc Analyses of the ARCHES trial . The present study relies upon secondary analysis of the ARCHES trial, a multinational randomized controlled trial th...
|
- Details
- In this presentation from Dan Petrylak, MD discusses the recent ARCHES study and offers an insightful perspective into radiographic progression-free survival (rPFS), in prostate cancer. The ARCHES study was a randomized phase 3 study of metastatic hormone-sensitive patients, looking at androgen deprivation therapy (ADT) with Enzalutamide, with a concurrent control group given a placebo, while also...
|
- Details
- In this Journal Club, Christopher Wallis and Zachary Klaassen highlight a subset analysis from the ENZAMET trial looking at the impact of enzalutamide on survival outcomes in men whose cancer comes back years later after diagnosis. The ENZAMET trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal...
|
- Details
- In a conversation with Alicia Morgans on clinical characteristics of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and identifying subsets of patients to improve personalized treatments, Christopher Sweeney shares data from a European Urology publication Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androge...
|
- Details
- Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...
|
- Details
- Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...
|